Our recent comparison study of GRP170-protein antigen complex vs. GRP170-peptide antigen in the setting of therapeutic immunization against cancer strongly supports the idea of including protein antigen in this vaccine regimen (48). The gene discussed is HYOU1; the disease is cancer.